An interventional study of National TeleOncology in Lung Cancer Diagnosis, Colorectal Cancer (Diagnosis) and Prostate Cancer Diagnosis, sponsored by NYU Langone Health. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Health services research
The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.
Study staff will use the Veterans Health Information Systems and Technology Architecture (VistA), the VA health information technology system, to identify eligible patients at VA sites based on listed inclusion and exclusion criteria. Patient records will be observed of Veterans with a new cancer diagnosis of the lung, prostate, breast, or colon and a telehealth visit utilizing the VA National TeleOncology Service (NTO).
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's planned enrollment of 1,800 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.
Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients Inclusion Criteria:
VAMC Providers and Staff Inclusion Criteria:
Patients Exclusion Criteria:
VAMC Providers and Staff Exclusion Criteria:
1. Providers or staff members who do not help treat Veterans with specified cancers in oncology at the VA
This arm will include 1. Veterans with a new cancer diagnosis of the lung, prostate, breast, or colon and a telehealth visit utilizing the VA National TeleOncology Service (NTO), and 2. VA health care providers and staff members participating in cancer care at NTO program medical centers.
Behavioral: National TeleOncology
This arm will include 1. Veterans with a new cancer diagnosis of the lung, prostate, breast, or colon and a visit at a VA medical center location that has not implemented NTO, and 2. VA health care providers and staff members participating in cancer care at a medical center where the NTO program has not been implemented.
Medical and/or subspecialty oncology care offered via facility-to-facility telehealth as an alternative to usual in-person care at the nearest VA or community oncology care setting offering similar services.
Number of raw telehealth visits
Telehealth utilization among Veterans with cancer will be measured through raw telehealth visit counts.
Time frame: Post-NTO implementation (up to 3 months)
Fraction of patients engaging in at least one telehealth visit
Telehealth utilization among Veterans with cancer will be measured by fraction of patients engaging in at least one telehealth visit.
Time frame: Post-NTO implementation (up to 3 months)
Change in provider level Quality Oncology Practice Initiative (QOPI) score
The quality of care of the intervention will be evaluating utilizing the American Society of Clinical Oncology Practice Initiative (QOPI) performance measures. The scale consists of 26 performance measures assessed at the patient, provider, and facility levels. Each cancer care provider will have his or her patient QOPI measures aggregated together for a provider level QOPI score. Our primary interest is the difference in QOPI score by intervention condition, as estimated by the fixed-effect coefficient for the intervention indicator variable. Scores of 75% or more indicate the standard is met, scores less than 75% indicate the standards have not been met. An increase in the QOPI score indicates improvement.
Time frame: Pre-implementation, post-NTO implementation (up to 3 months)
Time of consultation to time of first appointment
Time to care will be measured through time of consultation to time of first appointment.
Time frame: Pre-implementation, post-NTO implementation (up to 3 months)
Time of consultation to time of first treatment
Time to care will be measured through time of consultation to time of first treatment.
Time frame: Pre-implementation, post-NTO implementation (up to 3 months)
Average total cost for cancer diagnosis, treatment and downstream HealthCare utilization
Time frame: Post-NTO implementation (up to 3 months)
Plan to share: Yes — The de-identified participant data for survey and interview participants who have been consented and signed Health Insurance Portability and Accountability Act (HIPAA) waivers will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Per Veterans Health Administration (VHA) policy, the deidentified national data is unable to be shared. Requests may be directed to: janeth.juarezpadilla@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Sap
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NYU Langone Health